Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Reuters NewMedia - November 2, 2007
Favorable results for Viread in a similar late-stage trial were reported in June. In that 48-week study, about 71 percent of the 250 patients in the Viread arm had a complete response, compared with 49 percent in the Hepsera arm of 125 patients. Side effects were comparable in both treatment groups of the trial, which included some patients previously treated for hepatitis B.
The separate 266-patient study described on Friday compared the two Gilead drugs among patients who had never previously been treated for hepatitis B, an infection that over years can seriously harm or destroy the liver and increase the risk of liver cancer.
After 48 weeks of treatment, 67 percent of patients taking Viread had a complete response, compared with 12 percent of those taking Hepsera, Gilead said in a statement.
Both drugs were generally well tolerated, as in the separate previously reported Phase III trial, Gilead said. (Reporting by Ransdell Pierson, editing by Gerald E. McCormick)
071102
RE071102
Copyright © 2007 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .